Why Armata Pharmaceuticals, Inc.’s (ARMP) Stock Is Up 10.02%
As of Monday, August 03, Armata Pharmaceuticals, Inc.’s ARMP share price has surged by 10.02%, which has investors questioning if this is right time to sell.Cynthia McLaughlin
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Armata Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company that focuses on the development of targeted bacteriophage therapeutics for antibiotic-resistant infections worldwide. It develops its products using its proprietary bacteriophage-based technology. The company’s product candidates include AP-SA02 for the treatment of Staphylococcus aureus bacteremia; AP-PA03 for Pseudomonas aeruginosa . The company is based in Los Angeles, California. Armata Pharmaceuticals, Inc. is a subsidiary of Innoviva, Inc.
Commentary & Analysis
Why Armata Pharmaceuticals, Inc.’s (ARMP) Stock Is Down 9.32%
As of Tuesday, July 28, Armata Pharmaceuticals, Inc.’s ARMP share price has dipped by 9.32%, which has investors questioning if this is right time to buy.Michael Rose
Why Armata Pharmaceuticals, Inc.’s (ARMP) Stock Is Down 5.14%
As of Tuesday, July 21, Armata Pharmaceuticals, Inc.’s ARMP share price has dipped by 5.14%, which has investors questioning if this is right time to buy.Jenna Brashear
Why Armata Pharmaceuticals, Inc.’s (ARMP) Stock Is Up 16.19%
As of Monday, July 20, Armata Pharmaceuticals, Inc.’s ARMP share price has surged by 16.19%, which has investors questioning if this is right time to sell.Michael Rose
Why Armata Pharmaceuticals, Inc.’s (ARMP) Stock Is Up 5.23%
As of Friday, July 17, Armata Pharmaceuticals, Inc.’s ARMP share price has surged by 5.23%, which has investors questioning if this is right time to sell.Cynthia McLaughlin
Financial Summary
| Share Statistics | ARMP | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $172.5 | $277.2 | 26% |
|
| Shares Out (Mil) | 36.5 | 49.2 | 42% |
|
| Institutional Ownership | 95.2% | 92.1% | 67% |
|
| Float (Mil) | 11.4 | 40.0 | 21% |
|
| Beta | 1.23 | 0.94 | 72% |
|
| Avg Daily Volume (000s) | 95 | 485 | 35% |
|
| Price Change (52-week) |
73.4% | 55.5% | 86% |
|
| Growth | ARMP | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | 43.7% | 13.2% | 94% |
|
| Net Income (5yr) | (50.9%) | (10.0%) | 7% |
|
| EPS (5yr) | (28.9%) | 16.0% | 8 |
|
| Dividends (5yr) | 0.0% | 0.0% | 0% |
|
| Cash Flow (5yr) | (15.8%) | (15.6%) | 47% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | na | na | na | |
| Current EPS | ($0.380) | ($3.805) | ($1.340) | |
| Month Ago EPS | na | na | na | |
| # Rev Up | na | 0 | 1 | |
| # Rev Down | na | 0 | 0 | |
| Three Months Ago EPS | na | na | na | |
| Year/Year Chg | (88.0%) | (20.7%) | (78.5%) | |
| Financials | ARMP | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | $5 | $37 | 6% |
|
| Net Income (TTM) (Mil) | ($283) | ($43) | 5% |
|
| EPS (TTM) | ($7.780) | ($1.600) | 6% |
|
| Operating Cash Flow (TTM) (Mil) | ($24) | ($31) | 14% |
|
| Net Cash Flow (TTM) (Mil) | ($8) | $3 | 31% |
|
| Long-Term Debt (Q1) (Mil) | $369 | $3 | 58% |
|
| Enterprise Value (Q1) (Mil) | $626 | $162 | 38% |
|
| Valuation | ARMP | Industry Median |
Percentile (All Stocks) |
|
| P/B | na | 2.58 | na |
|
| P/E | na | 19.1 | na |
|
| Dividend Yield | 0.0% | 0.0% | 0% |
|
| PEG (5yr hist) | na | 0.9 | na |
|
| Ratios | ARMP | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | (215.2%) | 64.8% | 1% |
|
| Net Margin | na | (70.6%) | na |
|
| ROA | (359.9%) | (53.3%) | 1% |
|
| ROE | 154.7% | (60.8%) | 97% |
|
| Liabilities to Assets | 546.4% | 31.5% | 100% |
|
| F-Score | 2 | 3 | na |
|
Armata Pharmaceuticals, Inc. did not pass any screens on 8/5/2026.
